Background: Low-value services, such as prescribing brand-name medications that have existing generic equivalents, contribute to unnecessary health care spending.
H ealth care costs in the United States continue to rise and now account for more than $2.8 trillion annually (1) . It is estimated that as much as one third of this spending is due to unnecessary waste in the health care system (2) . The Choosing Wisely campaign is a joint initiative launched in 2012 by the American Board of Internal Medicine Foundation, Consumer Reports, and several medical societies (3) . Its premise is to decrease unnecessary spending by focusing on reducing the use of low-value services. Similarly, the American College of Physicians (ACP) has launched the High Value Care Initiative with the goal of helping physicians provide the best possible care for their patients while simultaneously reducing unnecessary costs to the health care system (4) .
Prescribing brand-name medications that have existing generic equivalents is a prime example of a low-value service. These medications are often more expensive than their generic equivalents, yet in most cases evidence suggests they are similar in effectiveness (5) . A recent study of 20 popular multisource drugs found that in 2009, Medicaid spent an additional $329 million that could have been saved by using existing generic equivalents instead of brand-name medications (6) .
The use of default options has been recognized as a successful strategy to change behavior in many settings, including health care (7) (8) (9) (10) . Default options are effective because they are often viewed as an implicit recommendation and because people tend to choose the path of least resistance. If a decision maker does not opt out, the default's action takes place (7) . Small changes in default settings can substantially affect medical decision making and provider behavior.
In January 2012, the Division of General Internal Medicine at the University of Pennsylvania in Philadelphia implemented an intervention to change the default in the electronic health record (EHR) medication prescriber with the goal of increasing the prescribing of generic equivalents when available. Before the intervention, if a provider searched for a brand-name medication, the options for prescribing brand names were shown near the top with generic equivalents listed below. After the intervention, if a provider searched for a brand-name medication, only the generic equivalent was listed. Providers still maintained the ability to opt out and conduct a broader search that listed the brand if warranted. The objective of this study was to evaluate the effect of this intervention on physician behavior related to the ordering of brand-name medications versus existing generic equivalents.
METHODS
The institutional review board at the University of Pennsylvania approved this study.
Setting and Participants
The sample comprised attending faculty and residents at 2 ambulatory clinics in the Division of General Internal Medicine (IM) and 2 ambulatory clinics in the Department of Family Medicine (FM) practicing between June 2011 and September 2012 at the University of Pennsylvania. All of these clinics were teaching practices where attending physicians practiced independently and served as preceptors for residents. The practices were located within the same ZIP code, and all providers used the same EHR. We classified providers by training level as attending physician or resident using publicly available listings of faculty and resident rosters (11) (12) (13) (14) , along with special request from the Internal Medicine Residency Program, Family Medicine Residency Program, Division of General Internal Medicine, and Department of Family Medicine.
Intervention
During the preintervention period (June to December 2011), both IM and FM providers used the same EHR medication prescriber and were shown the same resulting options. If a provider searched for a brand-name medication, the dosing options for prescribing brand names were listed at the top, with the dosing options for genericequivalent medications listed below (Figure 1) . During the postintervention period (January to September 2012), this remained unchanged for FM providers. However, if IM providers searched for a brand-name medication, the results listed only dosing options for generic-equivalent medications (Figure 2 ). The IM providers had the ability to opt out (by clicking on "Database Lookup" or pressing "F7" on the keyboard) and would then be shown the dosing options for brand names at the top, with the genericequivalent medications listed below.
Data
Provider prescription data were obtained by using EPIC's analytical reporting database, Clarity (EPIC Systems). These data reported the number of prescriptions per month by each provider that were sent electronically to the pharmacy for each medication included in the sample. When an electronic prescription is sent to the pharmacy, a patient can arrive without a paper copy and pick up the medications after presenting appropriate identification. Our reports capture all electronic prescribing from June 2011 to September 2012. Handwritten or faxed prescriptions were not captured by the reports produced for this study. Reports were produced as Excel files (Microsoft), coded, and then analyzed with Stata software, version 12 (StataCorp). 
Selection of Medications
We evaluated 3 classes of medications: ␤-blockers, statins, and proton-pump inhibitors (PPIs). Because we did not have access to data that allowed adjustment for patient characteristics, we chose these 3 medication classes because patients with indications for these medications are similar between the 2 specialties in our study, thus providing a better comparison between the intervention and control groups.
Among these 3 classes of medications, we excluded prescriptions for which a generic equivalent did not exist (e.g., Crestor [AstraZeneca]) to remove bias due to scenarios in which it was unclear whether prescribing a nonequivalent generic medication of the same class was not feasible or had already been done but was ineffective. We excluded combination medications to remove any bias related to scenarios in which the provider was attempting to decrease pill burden for the patient (for example, niacinsimvastatin extended-release) and an equivalent generic combination did not exist. We excluded prescriptions for Lipitor (Pfizer) and atorvastatin from the analysis because the generic equivalent had become available just 1 month before the intervention (30 November 2011) and there may have been alternative motives for switching between the brand and generic other than that related to the objective of our study. While this represented a large proportion of statins in the original sample, prescribing trends in the preintervention period differed because of the lack of a generic equivalent (see Data Supplement, available at www .annals.org).
The following medications and their associated brand-name equivalents were included in our sample: ␤-blockers (atenolol, carvedilol, labetalol, metoprolol, nadolol, and propranolol), statins (lovastatin, pravastatin, and simvastatin), and PPIs (lansoprazole, omeprazole, and pantoprazole).
Outcome Measures
To evaluate the effect of the intervention for IM providers compared with FM providers, we examined monthly prescribing trends of generic medication equivalents in the pre-and postintervention periods. Outcomes were evaluated for all providers (attending physicians and residents) for all medications in the sample and by medication class (␤-blockers, statins, and PPIs). Subset analyses were conducted to separately examine trends for attending physicians and residents because evidence suggests that these 2 groups may have differing practice patterns (15) (16) (17) . Residents are closer than attending physicians to medical school training, where generic medication names are more commonly taught and tested. Attending physicians are likely to be exposed to longer periods of industry detailing than are residents. In addition, interventions to change provider behavior may differ in effect among attending physicians, who have had longer to form practicing habits, than residents, who may be newly learning their practice style.
Statistical Analysis
For each measure, a multivariate logistic regression model was fit by using each prescription as the unit of analysis and clustering on provider. The effect of time was modeled by a dummy variable for each month. We evaluated the effect of the intervention by using an interaction term for provider specialty (IM vs. FM) and time to compare the proportion of generic medication prescriptions for each medication with itself before and after the intervention, contrasting the changes in IM to changes in FM. By using FM (not exposed to the intervention) as the control group in this study design, we reduce potential biases from unmeasured variables, such as general trends in prescribing behavior over time. Standard errors in the models were adjusted to account for clustering provider (18, 19) . We estimated the odds of prescribing a generic medication for IM providers compared with FM providers in the postintervention period relative to the preintervention period. To assess the mean effect of the intervention in the postintervention period, we exponentiated the mean of the monthly log odds ratios (ORs) and calculated a 95% CI for this quantity (20, 21) . We report the estimated probabilities of generic medication prescribing, which were derived from the logit model. In the Data Supplement, we report the odds ratios with 95% CIs for each month in the postin- 180  60  180  60  360  120  180  60  180  60   Tab  Tab  Tab  Tab  Tab  Tab  Tab  Tab  Tab  Tab Resulting medication dosing options after the intervention for internal medicine providers when a search for "Coreg" was conducted. Only the generic-equivalent options are listed; users have the ability to opt out and choose the brand-name if warranted. tervention period to evaluate the level and trajectory of changes in trend.
We performed a test of controls for the preintervention period (June to December 2011) to evaluate whether the null hypothesis of parallel trends between IM and FM trends could be rejected (22) .
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RESULTS
The study sample comprised 38 IM attending physicians, 17 FM attending physicians, 166 IM residents, and 34 FM residents ( Table 1 ). The rate of medications prescribed per month between the preintervention period and the postintervention period decreased slightly for IM attending physicians (21.1 vs. 18.7), increased slightly for FM attending physicians (14.9 vs. 17.0), and remained steady for IM residents (2.6 vs. 2.7) and FM residents (3.4 vs. 3.6).
During the preintervention period, FM providers had slightly higher rates of generic medication prescribing (range, 80.8% to 85.5%) than did IM providers (range, 75.4% to 79.6%) ( Table 2) . Test of controls for the preintervention period could not reject the null hypothesis of parallel trends between IM and FM providers (OR, 0.92 [95% CI, 0.71 to 1.20]; P ϭ 0.56).
In the postintervention period relative to the preintervention period, IM providers had an increase in generic prescribing compared with FM providers for all 3 medications ( Table  3) . Subset analyses between IM residents and FM residents were imprecise, with wide CIs (Table 4 ). This may have been due to the small sample size; therefore, we were unable to rule out meaningful changes in prescribing rates among residents.
DISCUSSION
We evaluated the effect of using default options within the EHR to change provider prescribing behavior in the ambulatory setting. Our study found that this intervention led to an increase in prescribing generic medications in the postintervention period when comparing providers in the intervention group to control. When we evaluated by medication class, the intervention was more effective for ␤-blockers and statins than for PPIs. In subset analyses by training level, we found similar trends among attending physicians. We did not find meaningful changes among residents, and this was probably due to limitations in sample size.
Several factors may be contributing to the findings in our study. First, PPIs were available over the counter, and this may help explain why the intervention was less effective for this medication class. Some patients may already have started a PPI and decided to use a brand or a generic equivalent. Second, residents had higher baseline rates of generic prescribing in the preintervention period than attending physicians, specifically among IM providers (Ta- bles 3 and 4). This may be explained by the fact that residents are closer to medical school training, where they are often taught only generic names of medications. In addition, because residents have been practicing for less time, they are less likely to have been exposed to as much pharmaceutical detailing as attending physicians. Furthermore, although IM attending physicians in the sample were informed directly about the intervention, residents were not; this may have contributed to its effectiveness. Third, results did trend toward higher increases in generic prescribing among IM residents than among FM residents, but small sample sizes (particularly among FM residents) may have limited our power to detect statistically significant changes. Fourth, monthly trend analysis reveals that although the intervention occurred in January 2012, it was not until March 2012 that provider behavior changed significantly. This may reflect a higher proportion of opt-outs immediately after the intervention was implemented that waned over time. This intervention demonstrates the use of default options within the EHR as a method applicable to reduce other low-value services that contribute to unnecessary health care spending (2) . Default options are best used when there is a clear alternative that is dominant from a value perspective (9) . Defaults have been demonstrated as a successful strategy to increase organ donor rates (23) (24) (25) and increase employee contributions to health savings accounts (26 -28) . Default options within an EHR may be more meaningful in changing behavior than are active alerts because of the well-documented fatigue that occurs over time with alerts (29 -31) . Changes in default options, such as the one in this study, can provide implicit recommendations to providers without giving more information (for example, an alert describing how generics are less expensive that brand names) or requiring additional steps to provide care (for example, an alert requiring an extra click or override). The evaluation of this intervention has important policy and clinical implications. Although all 50 states have some form of generic substitution laws, mandatory substitution laws exist in only 15 states (32) . Among the remaining 35 states, 80% require patient consent before generic substitution is allowed. A recent study found that states requiring patient consent had a 25% lower conversion to generic than states without such a law (33). Several recent studies demonstrated continued unnecessary spending on brand-name medications for which generic equivalents exist. An evaluation of 20 popular multisource drugs found that in 2009, Medicaid spent an additional $329 million that could have been saved by using existing generic equivalents instead of brand-name medications (6) . In another study, prescriptions for equivalent medication classes among diabetic patients were compared between Medicare enrollees and patients receiving care in the Veteran Affairs health system (34). After adjustment for patient characteristics and geographic variation, Medicare was observed to spend $1.4 billion more per year on brand-name medications than the Veterans Affairs health system. Even if mandatory generic substitutions laws were expanded to all 50 states, there is still concern that this interaction at the pharmacy might lead to confusion for the patient. Many patients require guidance to make medical decisions, and ge- neric substitution at the pharmacy leads to a situation in which the pharmacist is challenging the provider's implicit recommendation. Some patients may perceive that because generics are cheaper, they must be lower quality (35) . By using defaults within the EHR, providers may be more likely to prescribe generics to patients. This allows patients to have the opportunity to discuss brands versus generics while still in the clinic with the provider. It also helps avoid any unnecessary confusion or misperception on quality at the pharmacy. Our study is subject to several limitations. First, any observational study is susceptible to unmeasured confounding. However, by using FM as a comparison group, we reduce potential biases from unmeasured variables, such as general trends in prescribing behavior over time. Therefore, confounding would occur only if the prevalence of unmeasured risk factors changed at different rates between IM and FM providers. Second, the intervention and our data were limited to the setting of electronic prescribing, which accounted for most prescriptions in these practices. We did not have data on handwritten or faxed prescriptions and therefore could not evaluate whether differential trends existed in these settings. Third, our study excluded Lipitor and atorvastatin, about 30% of statins prescribed in the original sample (see Data Supplement), because the generic equivalent did not become available until 1 month before the intervention. While generic prescribing behavior for atorvastatin probably reflected different factors than other statins, we cannot rule out that generic availability of atorvastatin did not increase general awareness of generic availability of statins or affect statin prescribing in other ways. Fourth, our study did not evaluate trends beyond 9 months after the intervention. While rates of generic prescribing for IM providers were lower than those for FM providers in the last month of our study (September 2012), this change was not statistically significant in our model and may reflect usual variation. However, longer follow-up would be required for further evaluation. Finally, we did not have access to patient characteristics or pharmacy data and therefore were not able to adjust our model for these factors.
In conclusion, the use of an intervention to change default options within the EHR was an effective method to increase generic prescribing of ␤-blockers and statins when compared with a control group. These findings offer valuable insights for clinical decision-support teams evaluating interventions that could lead to sustained changes in provider behavior. Lessons from behavioral economics and specifically the use of default options within the EHR could be leveraged in other contexts to reduce unnecessary waste and improve the value of health care delivered to patients.
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